🇺🇸 FDA
Pipeline program

ARCT-021 Dose 1

ARCT-021-01

Phase 2 mab completed

Quick answer

ARCT-021 Dose 1 for SARS-CoV-2 is a Phase 2 program (mab) at Arcturus Therapeutics Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcturus Therapeutics Holdings
Indication
SARS-CoV-2
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials